Skip to content
Biodatica
Start free

Investigator

David E Kaplan

UNIVERSITY OF PENNSYLVANIA · funded by NCI, NIA

Companies
2

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$1.4M

Summed across those awards.

First award
Feb 1, 2023

Latest May 1, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant

    $442k

    May 1, 2025NCIUNIVERSITY OF PENNSYLVANIANIH RePORTER · 11132052 (opens the source filing in a new tab)

  2. R01

    The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant

    $526k

    May 1, 2025NCIUNIVERSITY OF PENNSYLVANIANIH RePORTER · 11324610 (opens the source filing in a new tab)

  3. R01

    Impact of mammalian target of rapamycin inhibitor therapy on aging-related outcomes

    $405k

    Feb 1, 2023NIAUNIVERSITY OF PENNSYLVANIANIH RePORTER · 11257275 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources